AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY19 results · Jan–Mar 2019
AstraZeneca Pharma India reported revenue from operations of ₹190.30 crore and net profit of ₹9.82 crore for Q4 FY19 (Jan–Mar 2019), on a standalone basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 190.30 | — | — | 215.19 | −11.6% |
| Other income | 6.01 | — | — | 3.50 | +72.0% |
| Total income | 196.31 | — | — | 218.69 | −10.2% |
| Profit before tax | 8.47 | — | — | 40.59 | −79.1% |
| Net profit for the period | 9.82 | — | — | 29.09 | −66.2% |
| EPS, basic (₹) | 3.93 | — | — | 11.64 | −66.2% |
| Net margin (%) | 5.2 | — | 13.5 |
Standalone
- Filed with BSE
- 25 May 2019, 11:35 IST
- Board meeting
- 24 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE